Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
-
Caspase-3, Coronin 1B, and Melanoma Motility
2026-08-21
A 2025 Cell Death and Disease study identifies a non-apoptotic role for caspase-3 in melanoma migration and invasion. The work links constitutive cytoskeletal caspase-3 to coronin 1B activity and places SP1 upstream of CASP3 expression, refining how apoptosis-associated proteins should be interpreted in cancer biology.
-
Gap19 for Cx43 Hemichannel Research
2026-08-20
Gap19 is a selective connexin 43 hemichannel blocker for separating Cx43 hemichannel signaling from gap junction communication. Its value spans astrocyte ATP-release assays, AngII-driven macrophage polarization, and translational models of cerebral ischemia, provided concentration, formulation, and route are controlled carefully.
-
2-D08: Selective Sumoylation Inhibition
2026-08-20
2-D08, also called 2’,3’,4’-trihydroxyflavone, is a selective posttranslational modification inhibitor that blocks SUMO transfer from UBC9-SUMO to substrate proteins. Its strongest reported application is mechanistic sumoylation inhibition in cancer research, including topoisomerase I sumoylation inhibition in breast cancer cells, while animal and clinical validation remains unavailable.
-
Caspase-3, NDUFS1, and ROS in Trichothecene Injury
2026-08-19
This non-peer-reviewed preprint identifies a caspase-3/NDUFS1 pathway that links trichothecene exposure to mitochondrial complex I disruption and ROS amplification, while also implicating ER-localized ERO1α as an independent oxidative source. Its combined in vivo, in vitro, inhibition, expression-suppression, and cleavage-site-mutant design offers a useful framework for separating mitochondrial dysfunction from broader oxidative stress.
-
Angiotensin I/II (1-5): RAS Workflow Guide
2026-08-19
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system experiments involving blood pressure and aldosterone-related readouts. It is intended for cardiovascular and renal research workflows, not unrelated peptide-signaling studies, and its water insolubility requires deliberate solvent and vehicle controls.
-
Prochlorperazine Workflows for Melanoma Research
2026-08-18
Prochlorperazine is a dopamine D2 receptor antagonist that can connect receptor pharmacology with practical melanoma, migration, and viral-entry assays. This workflow emphasizes concentration selection, solvent control, time-of-addition experiments, and troubleshooting so researchers can distinguish pathway-specific effects from general cytotoxicity.
-
Gentamycin Sulfate: From Ribosome to Resistance
2026-08-18
A translational framework for using Gentamycin Sulfate to connect bacterial protein synthesis, ribosome function, phenotypic susceptibility, and carbapenemase-gene transmission research in Gram-negative models.
-
Tetracycline Hydrochloride in Translational Research
2026-08-17
A mechanism-first guide to positioning Tetracycline Hydrochloride in antimicrobial assays, skin microbiome studies, and translational workflows—while distinguishing ribosomal inhibition from emerging ROS-based therapeutic strategies.
-
Biomimetic CaCO3 Nanoparticles for GBM Sono-Immunotherapy
2026-08-17
Zhao et al. developed cRGD-modified cancer-cell-membrane-coated calcium carbonate nanoparticles for IL-12 mRNA delivery to glioblastoma. The platform combines tumor targeting, ultrasound-triggered necroptosis, and cytokine expression to strengthen antitumor immunity, while also illustrating design principles for evaluating targeted mRNA delivery in difficult tissue environments.
-
Nirmatrelvir: From 3CLpro Mechanism to Assay Design
2026-08-16
Nirmatrelvir (PF-07321332) is a targeted SARS-CoV-2 3CL protease inhibitor for mechanistic antiviral research. This guide moves beyond basic mechanism to show how structural biology, docking evidence, compound handling, and orthogonal assay design can improve SARS-CoV-2 replication inhibition studies.
-
Gap26 in 3D Osteocyte Calcium Signaling
2026-08-15
Learn how Gap26 can turn a pulsatile fluid-flow osteocyte model into a controlled test of connexin 43-dependent calcium waves and ATP signaling. This workflow combines practical peptide handling, PUFFS-compatible dosing, quantitative imaging, and troubleshooting for more interpretable 3D mechanobiology experiments.
-
NBC19: A NLRP3 Inflammasome Inhibitor for Translation
2026-08-14
A translational framework for using NBC19 to connect NLRP3 biology, IL-1β signaling, and emerging evidence on circulating giant cancer macrophages and metastatic niche formation.
-
LDN-193189 in BMP Signaling: Practical Workflows
2026-08-14
Learn how to use LDN-193189 as a focused ALK inhibitor for dissecting BMP-driven epithelial degeneration, Smad signaling, and barrier phenotypes. This guide translates intestinal research into reproducible cell, tissue, and animal workflows while highlighting formulation limits and rescue-assay pitfalls.
-
Cichoric Acid in Sepsis-Induced Acute Kidney Injury
2026-08-13
The reference study identifies a mechanistic link between M1 macrophage polarization, SDH-associated metabolic disturbance, HIF-1α-driven glycolysis, and NLRP3 inflammasome activation in sepsis-induced acute kidney injury. Its mouse and RAW264.7 macrophage experiments suggest that cichoric acid protects renal tissue by jointly correcting inflammatory, metabolic, mitochondrial, and oxidative abnormalities.
-
Azilsartan (TAK-536) for RAS and CNS Models
2026-08-13
Azilsartan (TAK-536) provides a selective AT1-receptor perturbation strategy for separating renin–angiotensin signaling from microglia-derived inflammatory effects. This guide translates a reactive astrocyte workflow into practical concentration-response, conditioned-medium, readout, and troubleshooting decisions.